drugset / Trial / NCT03815279
A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)
Phase 2
Enrolling by invitation
80 enrolled
Landspitali University Hospital
Amgen · collabCelgene Corporation · collabMemorial Sloan Kettering Cancer Center · collabUniversity of Iceland · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the efficacy of treating patients with intermediate risk smoldering multiple myeloma (SMM) with combinational therapy with dexamethasone and lenalidomide (Rd) and patients with high risk SMM with combinational therapy with Rd and carfilzomib.
Timeline
- Start
- 2019-06-24
- Primary completion
- 2024-01
- Completion
- 2028-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carfilzomib | Other / unclassified | 56 mg/m2 | Intravenous |
| Subject | Dexamethasone | Small molecule | 10 mg | — |
| Subject | Lenalidomide | Other / unclassified | 10 mg | Oral |